SCCA Purpose & Mission
Seattle Cancer Care Alliance (SCCA) unites the doctors from Fred Hutch, UW Medicine, and Seattle Children’s into one world-class treatment center. SCCA was incorporated in 1998 as a separate, jointly governed non-profit that includes the cancer programs of the three partners. Each partner has equal ownership of SCCA. Dr. Fred Appelbaum is the Executive Director of SCCA.
- Provide state-of-the-art, patient and family centered care.
- Support the conduct of cancer clinical research and education.
- Enhance access to improved cancer interventions, and advance the standard of cancer care regionally and beyond.
Lead the world in translating scientific discovery into the prevention, diagnosis, treatment, and cure of cancer.
In 2014, more than 300 oncologists, surgeons, radiation oncologists, and many other clinicians treated over 6,000 patients for many types of cancers including leukemia and lymphoma, and breast, prostate, lung, and colon cancer. SCCA patients have access to the latest cancer treatments including stem cell and bone marrow transplantation, gene therapy, high-dose chemotherapy, radiation therapy, immunotherapy, minimally invasive surgical techniques, and other specialized therapies.
SCCA has five clinical care sites: an outpatient clinic on the Hutch campus, a pediatric inpatient unit at Seattle Children’s, an adult inpatient unit at UW Medical Center, a medical oncology clinic at EvergreenHealth, and medical and radiation oncology clinics at UW Medicine’s Northwest Hospital & Medical Center. Additionally, proton therapy services are provided at SCCA Proton Therapy, A Procure Center. If overnight hospital stays are necessary, adult patients go to UW Medical Center and pediatric patients go to Seattle Children’s Hospital.
Last year the Fred Hutch Bone Marrow Transplant Program at SCCA performed over 500 bone marrow transplants. The Center for International Blood and Marrow Transplant Research (CIBMTR) recently published the 2014 Transplant Center-Specific Survival Report, which recognized the Fred Hutch Bone Marrow Transplant Program at SCCA as one of 15 stem cell transplant programs nationwide that outperformed its expected one-year survival rate for patients undergoing “allogeneic” transplants.
A major focus of SCCA is to speed up the transfer of new diagnostic and treatment techniques from the research setting to patient care. The highly integrated approach to cancer research and treatment among SCCA partner organizations supports the flow of scientific information among researchers, clinicians, and patients, thereby accelerating the development of new knowledge and treatment of various cancers and blood disorders.